Rubius Therapeutics (NASDAQ:RUBY) Shares Gap Down to $26.15

Rubius Therapeutics, Inc. (NASDAQ:RUBY) gapped down prior to trading on Monday . The stock had previously closed at $26.15, but opened at $24.87. Rubius Therapeutics shares last traded at $24.73, with a volume of 3,876 shares trading hands.

A number of research firms have recently issued reports on RUBY. Morgan Stanley upped their price objective on Rubius Therapeutics from $10.00 to $24.00 and gave the stock an “equal weight” rating in a report on Monday, April 26th. HC Wainwright boosted their target price on Rubius Therapeutics from $28.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, March 22nd. Zacks Investment Research lowered Rubius Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 27th. Finally, SVB Leerink upped their price target on Rubius Therapeutics from $4.00 to $20.00 and gave the stock a “market perform” rating in a research note on Monday, March 22nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. Rubius Therapeutics has an average rating of “Hold” and an average price target of $23.50.

The firm has a market cap of $2.05 billion, a PE ratio of -11.79 and a beta of 2.37. The stock has a 50 day simple moving average of $24.88 and a two-hundred day simple moving average of $13.48. The company has a debt-to-equity ratio of 0.43, a quick ratio of 7.15 and a current ratio of 7.15.

Rubius Therapeutics (NASDAQ:RUBY) last announced its quarterly earnings results on Monday, May 10th. The company reported ($0.51) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.03. Equities research analysts forecast that Rubius Therapeutics, Inc. will post -2.11 earnings per share for the current year.

In related news, insider Maiken Keson-Brookes sold 25,000 shares of the stock in a transaction that occurred on Monday, March 15th. The stock was sold at an average price of $20.24, for a total value of $506,000.00. Following the completion of the transaction, the insider now directly owns 25,000 shares of the company’s stock, valued at approximately $506,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Ventures Fund Iv Gene Flagship acquired 210,000 shares of the firm’s stock in a transaction that occurred on Friday, March 19th. The stock was acquired at an average cost of $29.00 per share, with a total value of $6,090,000.00. The disclosure for this purchase can be found here. Corporate insiders own 58.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of RUBY. Citigroup Inc. boosted its stake in shares of Rubius Therapeutics by 42.7% during the 4th quarter. Citigroup Inc. now owns 10,953 shares of the company’s stock worth $83,000 after acquiring an additional 3,278 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Rubius Therapeutics during the 4th quarter worth $95,000. Centaurus Financial Inc. bought a new stake in shares of Rubius Therapeutics during the 4th quarter worth $118,000. ExodusPoint Capital Management LP purchased a new stake in shares of Rubius Therapeutics in the fourth quarter valued at $151,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Rubius Therapeutics by 17.3% in the fourth quarter. ProShare Advisors LLC now owns 20,425 shares of the company’s stock valued at $155,000 after purchasing an additional 3,015 shares in the last quarter. 93.74% of the stock is owned by hedge funds and other institutional investors.

About Rubius Therapeutics (NASDAQ:RUBY)

Rubius Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers.

Further Reading: How a Strangle Strategy is different from a Straddle Strategy

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.